Figure 1.

Therapeutic approaches targeting ECM proteins. ECM proteins within the TME have been selectively targeted by different approaches: Albumin-bound nab-Paclitaxel was shown to bind to SPARC-rich TMEs; MMP-inhibitors prevent the dissemination of basement membranes and vascular structures resulting in reduced tumor cell invasion; Hyaluronidases depolymerize HA and have suggested to make the TME permissive for immune cell infiltration and drug delivery; Prevention of FAK-phosphorylation prevents FAK activation resulting in increased sensitivity to chemotherapy and immunotherapy; Detection of the extradomain B of fibrinogen by immunocytokines has been proposed to facilitate specific antibody delivery of cytokines such as IL-2. (The displayed figure was partially generated with elements obtained from Servier Medical Art https://creativecommons.org/licenses/by/3.0/legalcode).